BioSpace News Archive

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg

Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that the company will present a poster and chair a panel at the American Association for Cancer Research Annual Meeting 2021, which is being held virtually from April 10-15.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that it will present at the Maxim Group Inaugural Emerging Growth Virtual Conference hosted by M-Vest.

Bristol Myers Squibb, the biopharmaceutical company that discovers, develops and delivers innovative medicines to help patients prevail over serious diseases, and Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, are excited to announce that Pierluigi Mantovani of Evolution Devices was chosen as the winner of the Addressing Unmet Needs in MS: An Innovation Challenge.

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the year ended December 31, 2020 and provided a business update.

NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation technology to treat neurological and neuropsychiatric disorders, announced that the following patents have issued or received notices of allowance in Canada and Japan:

Invacare Corporation priced $110 million aggregate principal amount of 4.25% convertible senior notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.